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Autologous haematopoietic stem cell transplantation has been tried as one experimental strategy for the treatment of patients
with aggressive multiple sclerosis refractory to other immunotherapies. The procedure is aimed at ablating and repopulating the
immune repertoire by sequentially mobilizing and harvesting haematopoietic stem cells, administering an immunosuppressive
conditioning regimen, and re-infusing the autologous haematopoietic cell product. ‘Non-myeloablative’ conditioning regimens
to achieve lymphocytic ablation without marrow suppression have been proposed to improve safety and tolerability. One trial
with non-myeloablative autologous haematopoietic stem cell transplantation reported clinical improvement and inflammatory
stabilization in treated patients with highly active multiple sclerosis. The aim of the present study was to understand the
changes in the reconstituted immune repertoire bearing potential relevance to its mode of action. Peripheral blood was obtained
from 12 patients with multiple sclerosis participating in the aforementioned trial and longitudinally followed for 2 years.
We examined the phenotype and function of peripheral blood lymphocytes by cell surface or intracellular staining and multi-
colour fluorescence activated cell sorting alone or in combination with proliferation assays. During immune reconstitution post-
transplantation we observed significant though transient increases in the proportion of CD4+FoxP3+ T cells and CD56high
natural killer cell subsets, which are cell subsets associated with immunoregulatory function. CD8+CD57+ cytotoxic T cells
were persistently increased after therapy and were able to suppress CD4+ T cell proliferation with variable potency. In contrast, a
CD161high proinflammatory CD8+ T cell subset was depleted at all time-points post-transplantation. Phenotypic characterization
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revealed that the CD161highCD8+ T cells were mucosal-associated invariant T cells, a novel cell population originating in the
gut mucosa but expressing the central nervous system-homing receptor CCR6. Detection of mucosal-associated invariant T cells
in post-mortem multiple sclerosis brain white matter active lesions confirmed their involvement in the disease pathology.
Intracellular cytokine staining demonstrated interferon  and interleukin 17 production and lack of interleukin 10 production,
a pro-inflammatory profile. Mucosal-associated invariant T cell frequency did not change in patients treated with interferon b;
and was more depleted after autologous haematopoietic stem cell transplantation than in patients who had received high-dose
cyclophosphamide (n = 7) or alemtuzumab (n = 21) treatment alone, suggesting an additive or synergistic effect of the condi-
tioning regime components. We propose that a favourably modified balance of regulatory and pro-inflammatory lymphocytes
underlies the suppression of central nervous system inflammation in patients with multiple sclerosis following non-myeloa-
blative autologous haematopoietic stem cell transplantation with a conditioning regimen consisting of cyclophosphamide and
alemtuzumab.
Keywords: stem cells; multiple sclerosis; T cells; proinflammatory cytokines; immune regulation
Abbreviations: AHSCT = autologous haematopoietic stem cell transplantation; IFN = interferon; IL = interleukin;
MAIT = mucosal-associated invariant T cell; TNF = tumour necrosis factor
Introduction
Multiple sclerosis is an inflammatory and neurodegenerative dis-
ease of the CNS (Compston and Coles, 2008). Current immune-
modifying treatments are incompletely effective in patients with
aggressive multiple sclerosis phenotypes. Autologous bone marrow
or haematopoietic stem cell transplantation (AHSCT) has been
experimented in patients with aggressive forms of multiple scler-
osis, aimed at suppressing CNS inflammatory activity and prevent-
ing further clinical deterioration (Saccardi et al., 2012). The
mechanistic rationale for AHSCT is to first purge the mature
immune system through intensive immune suppression and to
then promote—with haematopoietic stem cell support—the recon-
stitution of a new immune system, free from aberrant responses
that had previously developed within the individual’s adaptive
immune system.
Recent studies support a role for de novo regeneration of naı¨ve
T cells from the thymus (Hakim et al., 2005; Muraro et al., 2005),
for enhanced immune regulation after AHSCT (de Kleer et al.,
2006; Alexander et al., 2009; Zhang et al., 2009). In addition, a
recent study by Darlington et al. (2013) showed abrogation of the
T helper (Th)17 response following high-intensity AHSCT.
However, the cellular and molecular mechanisms underlying
improved clinical course post-AHSCT treatment are poorly under-
stood and further complexity is added by the use of different
immunosuppressive conditioning regimens. Non-myeloablative
conditioning regimens have been proposed to improve tolerability
and safety of AHSCT and allow treatment at earlier stages of
disease than in the initial clinical trials (Burt et al., 2010).
Current evidence for the immune modulatory mechanisms occur-
ring after AHSCT remains scarce and no study to our knowledge
has examined in detail the effects of a non-myeloablative condi-
tioning transplantation regimen on the immune system. One
recently published clinical trial of AHSCT using a non-myeloabla-
tive conditioning regimen in patients with highly active multiple
sclerosis has demonstrated sustained clinical stabilization in all and
even improvement of disability in some patients (Burt et al.,
2009). To investigate the immunological mechanisms underlying
the remission of CNS inflammation, we performed longitudinal
analysis of immune reconstitution in a group of patients treated
in that trial.
Our results show that following this non-myeloablative treat-
ment protocol using cyclophosphamide and alemtuzumab for im-
munosuppressive conditioning, there were significant transient
increases of CD4 + CD25highFoxP3+ T cells and of CD56high natural
killer cells, both phenotypes associated with immune regulatory
function. We also observed robust and long-term increase of
CD8 + CD57 + T cells post-AHSCT. CD8 +CD57 + T cells were, in
some patients, able to suppress CD4 + T cell proliferation in
ex vivo cell co-cultures with superior efficiency. In contrast, we
identified a population of CD161highCD8 + T cells that were readily
detectable in the blood of all patients pre-transplant, but were
maximally and permanently ablated during the 2-year post-
AHSCT follow-up. Further characterization of the CD161high
CD8 + T cell population found in multiple sclerosis patients’
blood pre-AHSCT revealed that these cells are mucosal-associated
invariant T (MAIT) cells, a T cell subset associated with the gut
(Le Bourhis et al., 2010; Dusseaux et al., 2011). High CD161-
expression defined a subset of pro-inflammatory T cells that
includes the majority of interleukin (IL)-17 producing CD8 +
T cells and also produces IFN- and tumour necrosis factor
(TNF)- but not IL-10. We confirmed that MAITs are able to mi-
grate to the brain as they were present in the white matter and
perivascular infiltrate of post-mortem multiple sclerosis brain
tissue. Comparison of MAIT frequency in patients that received
other multiple sclerosis treatments, including the individual com-
ponents of the conditioning regimen, high-dose cyclophosphamide
and alemtuzumab monotherapy, revealed that autologous haem-
atopoietic transplantation induced the most consistent depletion
for up to 2 years post-therapy.
The data demonstrate that the adaptive immune system
reconstituted in patients with multiple sclerosis following the
non-myeloablative AHSCT regimen is characterized by a favour-
ably modified balance of pro- and anti-inflammatory lymphocyte
subsets in the circulation, characterized by the expansion of immu-
noregulatory cells and radical depletion of a gut-associated
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CD161highCD8 + MAIT population, which produces IFN- and IL-
17, bears a pro-inflammatory profile and is able to infiltrate the
CNS.
Materials and methods
Subjects, treatment and biological
samples
Patients with aggressive multiple sclerosis who failed to respond to
licensed immune-modifying treatments were recruited for an institu-
tional review board-approved clinical trial of non-myeloablative
immunosuppressive conditioning with cyclophosphamide and alemtu-
zumab and AHSCT at Northwestern University, Chicago, USA (Burt
et al., 2009). Following informed consent, peripheral blood for the
research study was donated by subjects with multiple sclerosis
undergoing AHSCT in the trial (n = 12). The demographic and clinical
characteristics of the non-myeloablative AHSCT trial patients who
participated in this study are provided in Table 1. All these patients
underwent non-myeloablative conditioning with 120 mg/kg cyclo-
phosphamide and 20 mg alemtuzumab. Peripheral blood samples
were obtained from the AHSCT patients at baseline within 1 month
before haematopoietic stem cell mobilization, and at 6 months, 1 and
2 years post-haematopoietic stem cell reinfusion.
Peripheral blood mononuclear cell samples for comparative immuno-
logical analysis were obtained from non-AHSCT patients with multiple
sclerosis (n = 40), and healthy individuals (n = 7). Of the non-AHSCT
patients with sclerosis, five were untreated and seven received stand-
ard disease-modifying treatment with interferon-beta (IFN-b):
Betaferon (n = 5), Betaseron (n = 1) or Avonex (n = 1). The five
patients receiving Betaferon were studied longitudinally before and
during the first 9 months of treatment. One additional group included
patients who had participated in a study of high-dose cyclophospha-
mide (n = 7). Patients in this study received 50 mg/kg/day of cyclo-
phosphamide intravenously for four consecutive days, followed by
5 mg/kg/day of granulocyte colony stimulating factor 6 days after
completion of high-dose cyclophosphamide treatment, until the abso-
lute neutrophil count exceeded 1.0  109 cells/l for two consecutive
days. The protocol has been described in detail elsewhere (Krishnan
et al., 2008). Of the seven patients, five had pretreatment baseline
and post-treatment samples over a 2-year follow-up, one was
available only at pretreatment baseline, and one only at 2 years
post-therapy. The high-dose cyclophosphamide treated patients’ clin-
ical characteristics are given in Supplementary Table 1. The last group
of patients received alemtuzumab monotherapy (n = 21) by participat-
ing in one of four studies: CAMMS-224 (an investigator-led study,
REC 03/078); CAMMS-223 (a Phase 2 randomized controlled trial)
or CARE-MS1 or CARE-MS2 (Phase 3 randomized controlled trials).
Alemtuzumab was given for 5 days at baseline then for 3 days at
Month 12 (12 or 24 mg/day); further cycles were given if there was
clinical or radiological evidence of disease activity. All patients con-
sented to long-term follow-up and venipuncture for research purposes
(CAMSAFE REC-11/33/0007). Only post-treatment samples were
available for analysis. Demographic and clinical information on alem-
tuzumab-treated patients is provided in Supplementary Table 2.
Peripheral blood mononuclear cells were freshly separated by dens-
ity gradient centrifugation and cryopreserved according to rigorously
standardized protocols for subsequent use in batched, parallel immune
analysis. All laboratory studies received ethical approval from Imperial
College Research Ethics Committee (Ref. ICREC62D). T
ab
le
1
D
em
o
g
ra
p
h
ic
an
d
cl
in
ic
al
d
at
a
o
f
th
e
A
H
SC
T
p
at
ie
n
ts
Su
b
je
ct
co
d
e
Se
x
A
g
e
at
A
H
SC
T
(y
ea
rs
)
M
u
lt
ip
le
sc
le
ro
si
s
co
u
rs
e
D
u
ra
ti
o
n
o
f
d
is
ea
se
(y
ea
rs
fr
o
m
o
n
se
t)
P
re
vi
o
u
s
tr
ea
tm
en
ts
N
u
m
b
er
o
f
st
er
o
id
-t
re
at
ed
re
la
p
se
s
in
ye
ar
p
re
ce
d
in
g
tr
an
sp
la
n
t
P
o
st
-t
re
at
m
en
t
to
xi
ci
ty
M
u
lt
ip
le
sc
le
ro
si
s
re
la
p
se
s
p
o
st
-A
H
SC
T
ED
SS
sc
o
re
(p
re
-m
o
b
il
iz
at
io
n
b
as
el
in
e)
ED
SS
sc
o
re
(6
m
o
n
th
s
p
o
st
-A
H
SC
T
)
ED
SS
sc
o
re
(1
2
m
o
n
th
s
p
o
st
-A
H
SC
T
)
ED
SS
sc
o
re
(2
4
m
o
n
th
s
p
o
st
-A
H
SC
T
)
C
C
0
1
M
4
5
R
R
8
M
P
,
IF
N
-b
,
IV
IG
3
N
o
n
e
0
2
.0
1
.0
0
0
C
C
0
2
M
3
5
R
R
9
IF
N
-b
,
G
A
,
M
P
3
N
o
n
e
0
6
.0
5
.0
5
.0
3
.0
C
C
0
3
M
2
0
R
R
3
IF
N
-b
,
M
P
2
D
er
m
at
o
m
al
zo
st
er
at
2
0
m
o
n
th
s
0
3
.0
3
.0
1
.5
1
.5
C
C
0
4
M
4
4
SP
1
2
M
T
X
0
n
o
n
e
0
5
.5
6
.0
6
.0
6
.0
C
C
0
5
F
2
9
R
R
5
IF
N
-b
,
G
A
,
M
P
2
N
o
n
e
1
at
1
2
m
o
n
th
s
3
.5
2
.0
3
.5
2
.5
*
C
C
0
7
M
3
4
R
R
8
IF
N
-b
,
M
P
3
N
o
n
e
0
3
.5
3
.5
3
.5
2
.5
C
C
0
8
M
2
2
R
R
3
.5
IF
N
-b
,
P
E,
C
Y
,
M
P
2
N
o
n
e
1
at
1
2
m
o
n
th
s
5
.5
5
.5
6
.0
2
.0
C
C
0
9
M
3
6
R
R
4
G
A
,
IF
N
-b
,
D
C
Z
,
M
P
2
N
o
n
e
1
at
1
6
m
o
n
th
s
2
.5
1
.5
1
.5
1
.0
C
C
1
0
F
3
8
R
R
6
IF
N
-b
,
G
A
,
IV
IG
,
M
P
1
N
o
n
e
0
3
.5
2
.0
2
.0
2
.0
C
C
1
1
M
3
8
R
R
5
IF
N
-b
,
M
P
2
N
o
n
e
0
2
.5
2
.5
1
.5
2
.5
C
C
1
2
M
2
5
R
R
4
IF
N
-b
,
A
Z
A
,
M
P
2
N
o
n
e
1
at
6
m
o
n
th
s
3
.0
3
.5
3
.0
3
.0
C
C
1
3
F
5
3
R
R
2
IF
N
-b
,
M
P
2
IT
P
at
1
4
m
o
n
th
s
0
3
.5
2
.0
N
A
||
0
A
Z
A
=
az
at
h
io
p
ri
n
e;
C
Y
=
cy
cl
o
p
h
o
sp
h
am
id
e;
D
C
Z
=
d
ac
liz
u
m
ab
;
ED
SS
=
Ex
p
an
d
ed
D
is
ab
ili
ty
St
at
u
s
Sc
al
e;
G
A
=
g
la
ti
ra
m
er
ac
et
at
e;
IT
P
=
id
io
p
at
h
ic
th
ro
m
b
o
cy
to
p
en
ic
p
u
rp
u
ra
;
IV
IG
=
in
tr
av
en
o
u
s
im
m
u
n
o
g
lo
b
u
lin
;
M
P
=
m
et
h
yl
p
re
d
n
is
o
lo
n
e;
M
T
X
=
m
it
o
xa
n
tr
o
n
e;
N
A
=
n
o
t
av
ai
la
b
le
;
P
E
=
p
la
sm
a
ex
ch
an
g
e;
R
R
=
re
la
p
si
n
g
-r
em
it
ti
n
g
;
SP
=
se
co
n
d
ar
y-
p
ro
g
re
ss
iv
e.
*
A
ss
es
sm
en
t
at
3
6
m
o
n
th
s.
2890 | Brain 2013: 136; 2888–2903 S. V. Abrahamsson et al.
Flow cytometry
Peripheral blood mononuclear cells were thawed in Dulbecco’s PBS
and washed in fluorescence activated cell sorting staining buffer
(Dulbecco’s PBS, 1% foetal bovine serum and 0.01% sodium azide).
Surface staining was performed on ice for 20 min and the cells were
then analysed on a two laser, four colour FACSCalibur flow cytometer,
or for multicolour analysis on a five laser, 18 colour LSRFortessa
(Becton Dickinson). Data were analysed using CellQuest (Becton
Dickinson) and FlowJo software (TreeStar).
Immune reconstitution and phenotyping
studies
Multiplexed dilutions of monoclonal antibodies (mAbs) were used to
characterize lymphocyte populations. The following antibodies from
BD Biosciences were used: CD3-Cy-Chrome, CD3-RPE-Cy5, CD4-
RPE-Cy5, CD4-APC, CD5-APC, CD8-FITC, CD8-RPE-Cy5, CD8-
PerCP, CD8-APC, CD11a-PE, CD14-APC, CD19-FITC, CD20-PE,
CD25-FITC, CD25-PE, CD27-FITC, CD28-PE, CD31-PE, CD45RA-
FITC, CD45RA-PE, CD45RO-PE, CD45RO-APC, CD54-PE (ICAM-1),
CD56-PE, CD57-FITC, CD58-FITC (LFA-3), CD62L-PE, CD69-FITC,
CD95-PE, CD161-FITC (clone DX12), and T-cell receptor (TCR)b-
FITC. Other monoclonal antibodies included CD49d-FITC and
ILT2-PE (clone HP-F1) from Beckman Coulter.
Regulatory CD4+ cell quantification
Staining for CD3-PE-Cy7 (BD Biosciences), CD4-BV711, CD8-BV785,
CD25-BV421, CD45RA-BV510 (BioLegend), and CD127-FITC
(eBioscience) was performed before fixation and permeabilization of
the cells. Intranuclear cell staining was performed according to the
manufacturer’s instructions using FoxP3 Alexa Fluor 647 (clone
PCH101) and Ki-67 PerCP-eFluor710 (eBioscience). Blue Live/Dead
Stain (Life Technologies) was added to the samples before FoxP3
staining to for live versus dead cells discrimination.
Characterization of mucosal-associated
invariant T cells
Multicolour staining was performed with the following antibodies:
TCRV7.2-APC, TCRV7.2-PE (clone 3C10), CD4-BV711, CD4-
BV785, CD8-BV711, CD8-BV785, CD45RA-BV510, CD161-BV421
or CD161-BV605, CCR6 (CD196) PerCP-Cy5.5, from BioLegend;
CD161-PE and CD161-APC (clone 191B8) from Miltenyi Biotec;
CD3-PE, ILT2 (CD85j)-APC, ILT2-PE, CD150 PE and CD218 (IL-18R)
FITC from eBioscience; CCR6-PE from R&D Systems; CD3-APC-H7
and CD57 PE-CF594, CCR7 (CD197) PE-Cy7 (BD Biosciences) and
CD45RO-ECD (Beckman Coulter). Blue Live/Dead Stain (Life
Technologies) was included for exclusion of dead cells.
Characterization of T cell receptor
variable region expression
TCRV7.2-FITC and TCRV7.2-PE (clone 3C10) were obtained from
BioLegend. For TCRBV usage CD8 + T cells, peripheral blood mono-
nuclear cells were stained with anti-CD8-PerCP (clone SK3, BD
Bioscience) and anti-CD161-APC (clone 191B8, Miltenyi Biotec), in
combination with pairs of FITC and PE-conjugated antibodies to the
following TCRVb chains and assessed as previously described (Muraro
et al., 2000): BV1-PE (clone BL37.2), BV2-PE (clone MPB2D5), BV3-
FITC (clone CH92), BV5S1-FITC (clone Immu157), BV5S2-FITC (clone
36213), BV5S3-PE (clone 3D11), BV6S7-FITC (clone OT145), BV7-PE
(clone ZOE), BV8-FITC (clone 56C5.2), BV9-PE (clone FIN9), BV11-
FITC (clone C21), BV12-FITC (clone VER2.32.1), BV13S1-PE (clone
Immu222), BV13S2-PE (clone H132), BV14-PE (clone CAS1.13),
BV16-FITC (clone TAMAYA1.2), BV17-FITC (clone E17.5F3), BV18-
PE (clone BA62.6), BV20-PE (clone ELL1.4), BV21S3-FITC (clone
IG125), BV22-FITC (clone Immu546) and BV23-PE (clone AF23).
TCRBV6S7 was obtained from Endogen (Thermo Fisher Scientific),
TCRBV13S2 from Santa Cruz Biotechnology, and all other TCRBV
monoclonal antibodies were purchased from Immunotech.
Intracellular staining for cytotoxic
enzymes
Cytotoxic potential was assessed by intracellular staining after fixation
and permeabilization of the cells. Antibodies to perforin (PE) and gran-
zyme B (Alexa Fluor 647) were purchased from BD Biosciences.
Cytokine production assay
Peripheral blood mononuclear cells were stimulated for 5 h with
phorbol-12-myristate-13-acetate (PMA, 50 ng/ml) and ionomycin
(1 mg/ml) in the presence of brefeldin A (10 mg/ml, all from Sigma-
Aldrich), ex vivo after overnight recovery in cell incubator with RPMI-
1640 with 10% foetal bovine serum. The cells were harvested and
stained for relevant surface markers before fixation in 1% paraformal-
dehyde and permeabilization in 0.2% saponin. Intracellular cytokine
production was assessed by IFN- Horizon V450, TNF- PE-Cy7, IL-10
PE (BD Biosciences) and IL-17A Alexa Fluor 647 (eBioscience).
Suppression assays
Peripheral blood mononuclear cells were thawed and left to recover
overnight in RPMI-1640 with 10% foetal bovine serum and 20 U/ml
of IL-2. The following day, CD8 + CD57 + and CD8 + CD57 cells were
obtained from peripheral blood mononuclear cell using a magnetic
microbead kit from Miltenyi Biotec. The percentage of natural killer
cells found in all cases was45%. The CD8-depleted fraction was stained
with carboxyfluorescein succinimidyl ester (CFSE, Life Technologies)
and used as ‘effector’ (E) cells, while CD8 + CD57 + and CD8 + CD57
cells were used as ‘regulatory’ (R) cells. Co-cultures were conducted at
different R:E ratios in the presence of soluble anti-CD3 antibody (OKT3,
0.5 mg/ml, eBioscience). On Day 4, the cells were washed and stained.
Propidium iodide (1 mg/ml) was used for dead cell exclusion. The
percentage of cell proliferation was quantified on live (propidium
iodide-negative) CD4-gated cells. To normalize the data providing
from different donors, the proliferation in the absence of CD8 + cells
(0:1 ratio) was considered 100% and the normalized proliferation was
defined as the percentage of normalized proliferation at test ratio =
(% dividing cells at test ratio / % dividing cells at 0:1 ratio)  100, and
% suppression was defined as (100  % proliferation).
Immunostaining of multiple sclerosis
brain tissue
Brain tissue blocks were provided by the UK Multiple Sclerosis Tissue
Bank at Imperial College, London, UK. Post-mortem tissues were
collected with fully informed consent through a prospective donor
scheme with ethical approval by the National Research Ethics
Committee (08/MRE09/31). Tissue blocks were screened and chronic
active white matter lesions were identified as described previously
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(Magliozzi et al., 2007). Snap frozen brain white matter tissue blocks
containing active lesions were selected from a subset of nine cases
with progressive multiple sclerosis with high levels of CNS inflamma-
tion that formed part of a larger, well-described case series (Howell
et al., 2011). Tissue blocks (four per case) cut at 10mm, fixed for
10 min in ice-cold methanol and stained using a double sequential
immunofluorescence technique, first using anti-CD161 antibody
(clone: B199.2, AbD Serotec) followed by anti-V7.2 antibody
(clone: 3C10, BioLegend). Sections were incubated overnight at 4C
with the first primary antibody. Binding of biotinylated secondary anti-
body was visualized with the avidin-biotin horseradish peroxidase
complex (Vector Laboratories) followed by 30-min incubation with
tyramine (Sigma) in PBS containing 0.03% H2O2 according to a mod-
ified version of a method described by Adams (1992). The negative
control consisted in the same protocol without incubation with tyram-
ine. After 1 h incubation with Alexa Fluor 546-streptavidin
(Invitrogen) sections were washed, blocked with normal serum and
incubated overnight at 4C with the second primary antibody that
was then visualized with an Alexa Fluor 488 secondary antibody
(Invitrogen). Sections were counterstained with 4’,6-diamidino-2-
phenylindole (DAPI, Sigma) for the localization of the nuclei and
coverslipped with aqueous mounting medium Vectashield (Vector
Laboratories).
Statistical analysis
Statistical significance was calculated using unpaired t-test, or by
signed rank test for paired data that was not normally distributed.
For multiple group comparisons, statistical significance was evaluated
by parametric repeated measures ANOVA and Holm-Sidak’s post hoc
test, or if the normality test failed, by non-parametric ANOVA
on ranks and Dunn’s post hoc test. An overall P-value5 0.05 was
considered significant. Values are given as mean  standard deviation
(SD) for parametric comparisons, or median and interquartile range
(IQR) for non-parametric comparisons. Graphical presentations were
created with GraphPad Prism 5 and the statistical analyses were per-
formed using SigmaStat v3.1 software (Systat Software).
Results
Moderate contribution of thymic
reactivation to immune reconstitution
We first evaluated the basic lymphocyte reconstitution after non-
myeloablative AHSCT. Total absolute lymphocyte counts mea-
sured in whole blood were decreased up to the first year after
treatment. The proportion of CD4 + cells within the total T cell
population remained reduced for the entire 2-year follow-up
whereas no significant differences were detected in the percent-
ages of CD8 + T cells, hence CD4/CD8 ratios were persistently
decreased (Supplementary Fig. 1 and Supplementary Table 3).
Previous work from our group and others has shown that
AHSCT following myeloablative conditioning promoted increased
output of de novo generated naı¨ve T cells (Hakim et al., 2005;
Muraro et al., 2005). We now examined immune reconstitution
after non-myeloablative AHSCT through quantification of func-
tional differentiation stages of T cells, including naı¨ve (Tnaı¨ve), cen-
tral-memory (TCM), and effector memory (TEM) cells (Fig. 1 A and
Supplementary Table 3). Post-AHSCT the proportion of Tnaı¨ve cells
(CD45ROCD27 +) was unaltered in the CD4 + subset and
decreased in the CD8 + subset (from mean 61  14% at baseline
to 33  12% at 2 years, P = 0.001). Conversely, TEM
(CD45RO +CD27) cells constituted a larger proportion of the
total CD8 + pool than at baseline (from mean 4.2  3.0% to
26  14% at 2 years post-therapy, P50.001). There was a
trend to an increase of CD4 + TEM cells. These results suggested
that T cell reconstitution during the first 2 years post-transplant-
ation was predominantly driven by peripheral expansion.
To ensure that effective thymic output was not masked by per-
ipheral expansion (either antigen-driven or homeostatic) of naı¨ve
Figure 1 Moderate thymic reactivation during T cell reconsti-
tution. The proportions of peripheral blood T cells in functional
differentiation stages are shown at pretreatment baseline and at
indicated time points post-AHSCT. (A) Reconstitution of naı¨ve,
effector memory (TEM), and central-memory (TCM) cell popula-
tions are expressed as the percentage of cells CD4 + versus
CD8 + cells Statistical tests performed were repeated measures
ANOVA (naı¨ve CD4 + cells and all CD8 +) and non-parametric
ANOVA (CD4 TEM and TCM). (B) Reconstitution of recent
thymic emigrant (RTEs) CD4 + cells. The proportions of recent
thymic emigrants (CD31 + CD45RO) in the total and in the
naı¨ve (CD45RA + CD45RO) CD4 + cell populations are
increased after treatment. Statistical test performed was re-
peated measures-ANOVA. Pretreatment (PreTx) n = 11, 6
months (6 mo) n = 10, 1 year (1 yr) n = 10, 2 years (2 yrs) n = 7.
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cells resulting in conversion into effector/memory phenotypes, we
enumerated naı¨ve CD4 + T cells expressing CD31, a marker of
recent thymic origin (Kimmig et al., 2002). Such recent thymic
emigrant naı¨ve cells constituted a higher proportion of all CD4 +
cells at 1 year after therapy (from mean 30  12% to 45  18%,
a 50% increase, P = 0.025, Fig. 1B). Also the proportion of naı¨ve
CD45RA +CD45RO cells expressing CD31 was increased for up
to the first year post-AHSCT (from mean 73  13% to 84  9%,
P = 0.005). These results show that during the first 2 years after
non-myeloablative AHSCT the reconstitution of the circulating
T cell pool is dominated by the expansion in the periphery of
differentiated T cells acquiring effector cell phenotypes, with a
moderate but significant activation of thymic output.
Immunoregulatory cell surge early
post-therapy
To investigate the evolution of immunoregulatory cell populations
post-therapy, we used in our analysis a number of markers spe-
cifically defining regulatory lymphocytes. At 6 months post-AHSCT
there was a significant increase in the frequency of CD25high
CD127-FoxP3 + cells in the CD4 + T cell subset [from median
0.11% (IQR 0.03–0.20) to median 1.5% (IQR 0.9–1.9),
P = 0.002, Fig. 2A], as well as an expansion of CD56high natural
killer cells [from median 0.5% (IQR 0.3–1.3] to 3.7% (IQR
2.8–5.1), P = 0.001, Fig. 2B). The frequency of both cell subsets
subsequently returned to near baseline levels at 1 year after treat-
ment. The changes in the absolute counts were not significant
(Supplementary Table 3). These data show that the proportions
of regulatory T and natural killer cells are increased post-AHSCT.
Their transient increase may help modulate activated effector cells
during the early stages of antigen re-experiencing (O’Gorman
et al., 2009).
To assess whether the increased proportions of CD4 + regulatory
T cells were a result of increased homeostatic proliferation at
6 months, we assessed the expression of Ki-67, a cellular marker
for proliferation. Whereas the percentage of Ki-67-expressing cells
in the total CD4 + T cell population increased at 6 months (from
2.2  1.1% to 5.6  3.0%, P = 0.035; Supplementary Fig. 2A),
the percentage of actively proliferating regulatory T cells, which
was nearly four times that of the total CD4 + T cell population
at pretreatment baseline, did not change post-therapy (from
26  12% to 20  9%, P = not significant; Supplementary Fig.
2B). These results suggested that the increased relative frequency
post-transplantation of CD4 + CD25highFoxP3+ regulatory T cells
was not due to an increase in their proliferation rate.
We were also interested in the potential contribution to treat-
ment effect of CD8 +CD57 + cells, a suggested immunoregulatory
Figure 2 Post-therapy surge of lymphocytes with regulatory phenotype. A significant relative increase of cells with well-described
immunoregulatory phenotypes in major lymphocyte populations (CD4 + cells and natural killer cells) was detected at 6 months post-
treatment follow-up. (A) The figure shows the gating strategy and the percentages of FoxP3 +CD127CD25high in the CD4 + T cell
population. The cells were first gated on live CD25highCD4 +CD3 + cells and then on the FoxP3+CD127 populations. The numbers in the
dot plots indicate the percentages of FoxP3+CD127CD25high cells in the CD4 +CD3 + population T cells. Pretreatment (PreTx) n = 6,
6 months (6 mo) n = 6, 1 year (1 yr) n = 5, 2 years (2 yrs) n = 1. (B) Percentage of CD56high natural killer cells. Pretreatment (PreTx)
n = 11, 6 months (6 mo) n = 10, 1 year (1 yr) n = 10, 2 years (2 yrs) n = 5. Statistical test performed was non-parametric ANOVA.
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population (Autran et al., 1991; Mollet et al., 1998) that is sig-
nificantly increased in the periphery of patients with multiple scler-
osis after treatment with myeloablative AHSCT (Muraro et al.,
2005) as well as during treatment with glatiramer acetate (Ratts
et al., 2006). CD57 + cells occupied a significantly greater propor-
tion of the CD8 + T cell pool at all post-AHSCT time points when
compared with the baseline before haematopoietic cell mobiliza-
tion, reaching almost four times the baseline levels at 2 years post-
transplantation (from mean 16  9% to 59  13% of all
CD8 +T cells, P50.001; Supplementary Fig. 3A). CD8 + CD57 +
T cells after treatment were mainly effector memory cells
(not shown) that produced high levels of IFN-, granzyme B
(Supplementary Fig. 3B and C) and perforin (not shown). Their
phenotype was therefore consistent with that of classic cytotoxic
CD8 + T cells (Chattopadhyay et al., 2009).
To investigate the potential immunoregulatory ability of
CD8 +CD57 + T cells, we carried out suppression assays in which
CD8-depleted peripheral blood mononuclear cells (effector cells)
were stained with the vital dye carboxyfluorescein succinimidyl
ester (CFSE) and co-cultured with increasing numbers of
CD8 +CD57 + and CD8 +CD57 (‘regulatory cells’) in the presence
of a polyclonal (anti-CD3 antibody) stimulus. We then assessed
the inhibition of CD4 + T cell proliferation by measuring CFSE
dilution in effector cells after 4 days in culture in the presence
of both CD8 +CD57 + and CD8 +CD57 cells (Supplementary Fig
3D). The degree of inhibition by CD8 +CD57 + cells varied in dif-
ferent subjects and was either greater or equal to that of their
CD57 counterpart at all ‘regulatory’ to ‘effector’ (R:E) ratios
(Supplementary Fig. 3E). These experiments demonstrated that
cytotoxic CD8 +CD57 + T cells are massively increased in number
after AHSCT and, although CD57 was not a marker for inhibition
per se, the subset comprised in some patients cells with strong
suppressive activity.
CD161highCD8+ are radically depleted
after autologous haematopoietic
transplantation and are invariant T cells
associated with the gut mucosa
Extensive multi-colour fluorescence activated cell sorter phenotypic
characterization of pretreatment CD3 + CD8 + cells (data not
shown) revealed a distinct CD161highCD8high/dim population
(Fig. 3A). CD161highCD8 + T cell populations were present in the
Figure 3 CD161highCD8 are depleted following AHSCT and are MAITs. The CD161high cells represented on average 8% of the
CD8 +CD3 + cell population and were almost undetectable after the therapy with AHSCT. (A) Representative example of CD161 expression
by CD8 +CD3 + cells in one patient at pre-therapy and at indicated time-points after AHSCT. (B) The box plots represent the proportion of
CD161high CD8 +CD3 + cells at pretreatment and at indicated time points after AHSCT. Pretreatment (PreTx) n = 11, 6 months (6 mo) n = 9,
1 year (1 yr) n = 8, 2 years (2 yrs) n = 6. (C) Representative example of MAIT markers expressed by CD161highCD8 + cells show an almost
exclusive usage of TCR V7.2 and expression of IL-18R, CCR6, and CD150. (D) Difference in T cell receptor beta variable (BV) gene
expression of CD161highCD8 + cells with reference to the total CD8 + population [% BV (CD161highCD8  all CD8 cells)] shows a prefer-
ential usage of Vb2 and Vb13.2 by CD161highCD8 + cells (red boxes, n = 7). The bars indicate the mean and standard deviation. Asterisks
indicate significant P-values (50.05, unpaired t-test). BV = T cell receptor beta variable (BV) gene.
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blood of all the patients before treatment (mean 7.8  3.2% of
total CD8 +CD3 + cells). Of note, this population was radically
depleted after AHSCT, and remained nearly undetectable for the
whole follow-up period of 2 years (P50.001; Fig. 3B).
High expression of CD161 in CD8high/dim T cells defines the
MAIT subset (Dusseaux et al., 2011), a CD4 T cell subset
defined by the expression of innate immune receptors and usage
of the semi-invariant TCR V7.2-J33 (Treiner et al., 2003), with
a preferential Vb2 and Vb13 gene expression (Tilloy et al., 1999;
Treiner et al., 2005). We confirmed that 490% of the
CD161highCD8 + T cell population in patients with multiple scler-
osis expressed TCR V7.2 and that high expression of CD161 was
associated with expression of IL-18R, CCR6 and the SLAM mol-
ecule CD150 (Fig. 3C), consistent with a recent defining descrip-
tion of MAITs (Dusseaux et al., 2011). In contrast, a high
expression of CD161 in the less frequent CD4CD8 T cell
subset did not identify MAITs per se, as a large proportion of
these CD4CD8CD161high cells did not express V7.2
(Supplementary Fig. 4A). The CD161highCD8 + subset was also
enriched in cells expressing TCR Vb2 (mean 15.4  6.4% of
CD161highCD8 + ) and Vb13.2 (mean 7.3  3.3%), consistent
with MAITs, and readily appreciated when expressed as the
difference of TCR expression in the CD161highCD8 + T cells com-
pared with all CD8 + T cells (Fig. 3D). The CD161highCD8 + T cell
population showed a pattern of markers typical of antigen primed
(CD45RACD45RO +CD27 + /CD28 + CD62L) effector memory
cells (Supplementary Fig. 4B).
CD161highCD8+ mucosal-associated
invariant T cells are proinflammatory
To assess the cytokine profile of CD161high, CD161dim, and CD161
CD8 + T cells, we carried out intracellular cytokine staining.
CD161highCD8 + T cells from patients with multiple sclerosis before
AHSCT produced the pro-inflammatory cytokines IFN-, TNF-, and
IL-17 (Fig. 4 A), but not the immunoregulatory IL-10 (results not
shown). Of all CD8 + subsets, the CD161highCD8 + subset contained
the highest frequency of IFN- (77  4%, P50.001, Fig. 4B) and
TNF- producing cells (56  12%, P50.001, Fig. 4C). The frequen-
cies of CD8 + T cells producing IL-17 tended to be higher in the
CD161high (mean 1.76  1.57% and 1.15  1.4%, P = 0.040,
Fig. 4D), but the analysis was not powered to detect the differences
between the groups. However, the CD161highCD8 + subset had
the highest frequencies of cells producing both IL-17 + and IFN-
(mean 0.82  0.69%, P = 0.002, Fig. 4E).
When comparing the frequencies of CD161high, CD161dim, and
CD161 cells within the cytokine-producing CD8 + T cells, the
majority of the cells producing the widely expressed IFN- and
TNF- were CD161CD8 + cells (that constitute 80–90% of the
CD8 + T cell pool). Despite their considerably smaller numbers,
CD161high cells constituted half of the total IL-17 + (mean
49  28%) and IL-17 + IFN- + double positive cells (mean
51  26%, Fig. 4F).
Together these data confirmed that the CD161highCD8 + T cells
present in patients with multiple sclerosis before treatment and
ablated post-therapy were proinflammatory effector MAITs,
which contained a major fraction of IL-17 producing and
IL-17/IFN- co-producing CD8 + T cells.
Mucosal-associated invariant T cells are
present in multiple sclerosis lesions
The almost exclusive expression of CCR6 on CD8 + MAITs sug-
gested their ability to enter the CNS (Reboldi et al., 2009). We
then investigated whether CD161-expressing MAITs were also
present in multiple sclerosis lesions in post-mortem brain tissue
from nine cases with high levels of inflammatory CNS infiltration.
Staining with antibodies against CD8 and CD161 revealed the
presence of double positive CD161 +CD8 + cells within the inflam-
matory infiltrates of chronic active white matter lesions (Fig. 5A).
Since distinction of the CD161high versus CD161dim + cells is not
possible in tissue, we also stained for TCRV7.2, which together
with CD161 defines the MAIT population. We confirmed by dual
immunofluorescent staining that CD161 and TCRV7.2 double
positive MAITs were indeed present in white matter lesion inflam-
matory infiltrates in all nine multiple sclerosis cases (Fig. 5B and C).
The presence of MAITs in active white matter lesions in the
multiple sclerosis brain suggested their involvement in multiple
sclerosis pathogenesis, based on their cytokine profile, possibly
as proinflammatory effectors.
Circulating mucosal-associated
invariant T cell numbers are
differentially affected by diverse
immunotherapies
We next asked whether depletion of MAITs in the periphery was
specific for the autologous haematopoietic transplantation proto-
col and to which extent other treatments for multiple sclerosis
affected MAIT frequencies. We first confirmed the depletion of
CD161highV7.2 + CD8 + MAITs from the periphery of AHSCT
patients (Fig. 6A). After AHSCT, the frequencies of CD8 +
MAITs decreased (from a mean 12.1  7.4% of CD8 + cells at
baseline, to mean 0.6  0.2% at post-therapy follow-up 2 years,
P50.001, Fig. 6B). In contrast, the frequency of CD161highCD8 +
cells, a good surrogate of CD8 + MAITs (Supplementary Fig. 4A) in
the blood of patients treated with IFN-b was unchanged 6 months
after treatment (Supplementary Fig. 5).
We then set out to dissect the effects on MAITs in vivo from
each of the two components of the immunosuppressing condition-
ing regime, cyclophosphamide and alemtuzumab, by studying per-
ipheral blood mononuclear cell samples from patients who had
been treated with either high-dose cyclophosphamide or alemtu-
zumab alone. We measured the frequencies of CD8 + MAITs at
pre-therapy baseline and at 2 years post-therapy in five patients
who underwent immunosuppression with high-dose cyclophos-
phamide. An additional two patients had only pre- or post-therapy
samples available. The CD8 + MAITs were profoundly reduced in
four of six patients, but persisted at high levels post-therapy in
two subjects (Fig. 6C). We also measured MAIT frequency in pa-
tients who received treatment with alemtuzumab monotherapy
(n = 21). Patient samples were taken at different time points
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after the last alemtuzumab infusion (range 2–38 months); how-
ever, the time seemed not to affect the CD8 + MAIT frequencies
within the sampled period as they did not correlate with the time
after treatment (Fig. 6D).
When comparing AHSCT, high-dose cyclophosphamide and
alemtuzumab monotherapy post-treatment samples, MAIT frequen-
cies in both the CD8+ (Fig. 6E) and the CD4CD8+ (Fig. 6F) cell
subsets, as well as in the total CD3+ population (Fig. 6G) were low
in all three groups, being lowest in the AHSCT-treated patients.
MAITs in all subsets (CD8+ , CD4
 and CD3+) were significantly
higher in the high-dose cyclophosphamide patient samples com-
pared with both the AHSCT and alemtuzumab (monotherapy) trea-
ted patients (CD8+ MAITs: P = 0.011; CD4 MAITs: P = 0.004;
CD3+ MAITs: P = 0.002). These results were driven by MAIT num-
bers remaining high in two of six high-dose cyclophosphamide pa-
tients. Whereas the mean frequencies were not statistically different
between AHSCT and alemtuzumab treated patients (t-test, CD8+
MAITs: P = 0.09; CD4 MAITs: P = 0.12: CD3+ MAITs: P = 0.07),
the variance between the two patient groups was different (F-test,
CD8+ MAITs: F5 0.001: CD4 MAITs: F = 0.006: MAIT/total
CD3+: F = 0.012), indicating that the frequencies of all MAIT popu-
lations were differently distributed in the two treatment groups,
with a greater variability of MAIT numbers in the alemtuzumab
monotherapy treated group.
Relationship of circulating
mucosal-associated invariant T cell
frequency with clinical response
to treatment
Our study was not designed to ascertain if a correlation might exist
between the degree of activity after the treatments. We attempted,
however, to detect a potential association by stratifying patients
according to post-therapy circulating CD8 + MAIT frequency and
examining their clinical course. As the putatively therapeutic range
of depletion of MAITs is unknown, we applied statistical cut-off
values to stratify patients in groups having low, intermediate and
high post-therapy MAIT frequencies (Supplementary Fig. 6). The
patients who underwent AHSCT had predominantly low (50.8%)
and none had high (42.38) frequencies of circulating CD8 + MAITs
at any time point post-therapy. There were only two post-therapy
samples that had intermediate (0.8–2.38%) CD8 + MAIT frequency
in the AHSCT cohort (n = 12) and they were the 12-month sample
from Patient CC09 who relapsed at 16 months and the 6-month
sample from Patient CC12 who relapsed at 6 months (CD8 MAIT
frequencies 1.1% in both). Interestingly, CD4 + T cells in the sample
associated with relapse at 6-month follow-up showed a greatly
enhanced proliferation to myelin basic protein (Supplementary
Fig. 7). The remaining two patients who had a relapse after
AHSCT (both at 12 months), however, had low MAIT frequencies
at all the post-transplantation time points assessed. In the high-dose
cyclophosphamide treated cohort (n = 6 with post-therapy samples)
there were two patients (Patients HiCy1 and HiCy2) who had high
MAIT frequency post-therapy (10.4% and 15.7%, respectively).
Notably, they were also the two patients with highest MAIT
frequency at the pretreatment baseline (13.8% and 17.0%,
Figure 4 CD161highCD8 + cells are proinflammatory MAITs.
Characterization of CD161highCD8 + cells in multiple sclerosis
patients. (A) Representative example of cytokine production by
CD8 +CD3 + cells in function of CD161-expression. Peripheral
blood mononuclear cells from patients before treatment were
stimulated in culture with phorbol-12-myristate-13-acetate
(PMA) and ionomycin after overnight recovery in cell incubator.
The contour blots show the production of IFN-, TNF-, and IL-
17 by the total CD8 +CD3 + populations, and by CD161high,
CD161dim and CD161 CD8 + T cells. (B–E) The scatter plots
show the percentage of cytokine producing cells in the total
CD8 +CD3 + population, and in CD161high, CD161dim and
CD161 CD8 + T cells: (B) IFN-, (C) TNF-, (D) IL-17, and (E)
IL17 + IFN- + cells. (F) The distribution of CD161high, CD161dim
and CD161neg in the total cytokine-producing population is
shown, and expressed as a percentage of cytokine +CD8 + T cells
(n = 7). Statistical tests performed were non-parametric
ANOVA.
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respectively), and the highest disability both pretreatment
(Expanded Disability Status Scale 7) and post-treatment
(Expanded Disability Status Scale 6.5 and 7, respectively) in the
cohort (Supplementary Table 1). Of these two patients, one
(Patient HiCy1) had a stable post-treatment course; the other
(Patient HiCy2) had a high inflammatory activity in the CNS,
with 20 gadolinium-enhancing lesions at Month 27 post-therapy.
The clinical course post-therapy in high-dose cyclophosphamide
treated patients with intermediate (Patients HiCy3 and HiCy4)
or low (Patients HiCy6 and HiCy9) MAIT frequencies was variable
(Supplementary Table 1). In the larger cohort of alemtuzumab-only
treated patients (n = 18 after excluding three patients who were
being treated with IFN-b at the alemtuzumab baseline, in order to
avoid potential confounding effects on the clinical measures) a fair
range of MAIT levels and of disease activity following therapy were
documented (Supplementary Fig. 6A). Of note, the two patients
with high frequency of CD8 MAITs after alemtuzumab treatment
(Patients Alem10 and Alem20, 3.56% and 7.43% CD8 MAIT at 24
months and 12 months since last infusion of three courses of alem-
tuzumab, 80 months and 66 months since first infusion, respect-
ively) had highly active multiple sclerosis before treatment (both
had three relapses in the preceding 12 months), were at the high
end of the range of disabilities at baseline within the cohort
(Expanded Disability Status Scale 6 and 6.5, respectively) and
relapsed during a long-term post-treatment follow-up (four relapses
and one relapse; annualized relapse rate 0.6 and 0.18, respectively).
Their disability, however, markedly improved after alemtuzumab
treatment; Patient Alem10 had Expanded Disability Status Scale
2.5 and Patient Alem20 had Expanded Disability Status Scale 3.5
at their last assessments (at 80 months and at 74 months, respect-
ively, since the first course of alemtuzumab). In the low- and inter-
mediate CD8 MAIT frequency group there were four patients who
had no relapses post-treatment (two and two, respectively); one or
more relapses post-therapy over a variable duration of follow-up
were documented in five of seven and eight of ten patients in these
groups, respectively (Supplementary Fig. 6B–D).
Discussion
In this study we investigated the immune reconstitution in patients
who underwent non-myeloablative conditioning AHSCT for
Figure 5 CD8 + CD161 + and MAITs are present in perivascular infiltrates within chronic active lesions in the brain of patients with
multiple sclerosis. (A) An example of CD8 + (green) and CD161 + (red) single and double positive cells (indicated by white arrows) within
the inflammatory cellular infiltrates of chronic active white matter (WM) lesions in the brain of a patient with multiple sclerosis. (B and C)
CD161 + (green) and TCRV7.2 + (red) double positive MAITs are also found in white matter lesions inflammatory infiltrates. Blue (DAPI)
stains all nuclei. All images were acquired at 20 magnification except C at 40. All scale bars = 20 mm. BV = blood vessel.
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treatment of their highly active, conventional treatment-resistant
forms of multiple sclerosis. We observed immunological changes
that were consistent with a favourably redistributed balance of
regulatory versus proinflammatory lymphocytes, resulting from
the relative increase of cells with regulatory profile and the radical,
virtually complete depletion of a CD8 + T cell subset expressing
high levels of CD161 and producing IFN-, TNF-, and IL-17.
Based on their chemokine and cytokine receptor profile as well
as its semi-invariant T cell receptor rearrangement, we character-
ized CD8 +CD161high cells as MAITs and demonstrated their pres-
ence in brain white matter lymphomononuclear cell infiltrates in
post-mortem multiple sclerosis white matter tissue, supporting its
potential pathogenic relevance.
Different AHSCT conditioning regimens have been explored for
treatment of aggressive forms of immune-mediated disorders.
Non-myeloablative regimens have been proposed for two main
Figure 6 Effects of high-dose cyclophosphamide monotherapy and alemtuzumab monotherapy on MAIT frequency. MAITs defined by
the expression of V7.2 and CD161 are reduced following AHSCT and reduced after monotherapy with high-dose cyclophosphamide
(HiCy), and after alemtuzumab alone (Alem). (A) Representative dot plots gated on live CD3 +CD8 + cells, showing expression of
TCRV7.2 on the x-axis and CD161 on the y-axis. (B) Frequencies of MAITs (V7.2 +CD161high) in patients with multiple sclerosis before
and after AHSCT. Note the segmented y-axis. Pretreatment (PreTx) n = 10, 6 months (6 mo) n = 9, 1 year (1 yr) n = 7, 2 years (2 yrs)
n = 3. Statistical test was repeated measures-ANOVA. (C) Frequencies of MAITs in patients with multiple sclerosis before and after
receiving high-dose cyclophosphamide. Patients with samples available at both time points are connected with a line. Note the segmented
y-axis. Pretreatment (PreTx) n = 6, 2 years (2 yrs) n = 6. Statistical test performed was paired t-test. (D) Frequency of CD8 + MAITs in
peripheral blood mononuclear cells of patients (n = 21) collected at different time points after their last infusion of alemtuzumab. The
middle line represents the mean and the sideline the confidence interval (95% onfidsence interval). (E–G) Comparison of MAIT fre-
quencies in patients receiving AHSCT (n = 11, range 6–24 months post-therapy) monotherapy with either high-dose cyclophosphamide
(HiCy, n = 6, 24 months post-therapy) or alemtuzumab (Alem, n = 21, range 2–38 after last infusion).
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reasons: (i) the treatment should primarily target the lymphoid,
not the myeloid compartment; and (ii) improved safety and toler-
ability facilitate treating patients during the appropriate window of
therapeutic opportunity at earlier stages of disease (Burt et al.,
2008). A recent clinical trial showed that non-myeloablative
AHSCT can arrest or reverse neurological deterioration in patients
with highly active, treatment-resistant relapsing-remitting multiple
sclerosis with acceptable safety (Burt et al., 2009). Here we
investigated key aspects of immune reconstitution in 12 patients,
who had all received the same (cyclophosphamide/alemtuzumab)
non-myeloablative conditioning regimen in that trial.
Analysis of the naı¨ve and memory T cell repertoire after non-
myeloablative conditioning AHSCT revealed a markedly different
quality of immune reconstitution when compared with our previ-
ous study of a myeloablative conditioning regimen using cyclo-
phosphamide and total body irradiation (Muraro et al., 2005).
Whereas naı¨ve T cells following cyclophosphamide and total
body irradiation had a biphasic reconstitution with initial depletion
followed by recovery and increase to twice their baseline fre-
quency (Muraro et al., 2005), in the present study the frequencies
of naı¨ve CD4 + T cells and of naı¨ve CD8 + T cells were unchanged
and reduced throughout the post-therapy follow-up. We detected,
however, a moderate but statistically significant degree of CD4 +
recent thymic emigrant expansion during the first year of follow-
up, demonstrating a degree of reactivation of the thymus.
Together, these results suggest that the non-myeloablative condi-
tioning regimen that we investigated in our study induced a less
extensive replacement of the mature T cell repertoire than the
previously reported myeloablative regimen. We have used CD31
as an established marker to enumerate T cells recently differen-
tiated from haematopoietic stem cells; however, these methods
cannot distinguish whether the haematopoietic stem cells were
survivors from the bone marrow or from the infused autologous
graft. Since a non-myeloablative conditioning protocol by defin-
ition causes minimal bone marrow suppression, it is likely that
haematopoietic stem cells from both the patient’s bone marrow
and the graft contribute to immune reconstitution.
These results prompted us to hypothesize that the therapeutic
effect of AHSCT on CNS inflammation in multiple sclerosis may
not require a complete renewal of the T cell repertoire but could
be mediated by the normalization of a balance between pro-
inflammatory and immunoregulatory cells. Abnormalities in the
number or function of CD4 + regulatory cells have been previously
reported in multiple sclerosis (Viglietta et al., 2004; Venken et al.,
2008). Our longitudinal analysis of regulatory T cell frequency
showed a significant surge in CD4 + CD25 + CD127FoxP3 + cell
proportions relatively early (6 months) post-transplantation.
These results are consistent with previous work in juvenile idio-
pathic arthritis and in systemic lupus erythematosus, suggesting
that recovery of CD4 +CD25high T cells might play a role in the
mode of action of AHSCT (de Kleer et al., 2006; Alexander et al.,
2009). Expansion of CD4 + regulatory T cells has also been shown
after alemtuzumab monotherapy (Cox et al., 2005) leaving open
the possibility that increased regulatory T cell numbers are part of
a common response following intensive lymphodepletion.
We considered the possibility that the transiently increased
numbers of regulatory T cells after AHSCT were the result of a
boosted homeostatic proliferation at 6 months. Regulatory T cells
had a higher proliferation than the whole CD4 + population at
baseline and there was no change at 6 months post-therapy, des-
pite that the total CD4 + patient population was proliferating
much more actively than at baseline. These results suggest that
increased active proliferation did not account for the higher num-
bers of regulatory T cells post-transplantation; rather, it appears
that regulatory T cells either are more resistant to the immuno-
suppressive regime or they recommence to be exported from the
thymus and steadily proliferate in the periphery, with a gain of
their relative proportion in the lymphopenic CD4 + compartment,
which is likely to give them a regulatory advantage over re-emer-
ging effector T cells.
We also describe a transient increase of CD56high natural killer
cells, a natural killer cell subset with immunoregulatory potential
(Jiang et al., 2011). CD56high natural killer cells have been
reported to expand and mediate therapeutic effects in patients
with multiple sclerosis treated with daclizumab (Bielekova et al.,
2006) and IFN-b (Vandenbark et al., 2009). We speculate that the
early expansion of CD4 + regulatory T cells and regulatory CD56high
natural killer cells may be important for the control of the immune
system during the early antigen priming of re-emerging lympho-
cytes, as previously suggested (O’Gorman et al., 2009).
Next, we focused our analyses on the functional significance of
different types of phenotypic CD8 + T cell effector memory cell
subpopulations, which demonstrated significant changes in their
frequencies in pre- to post-AHSCT blood samples. We have pre-
viously reported a prominent increase of CD57 + CD28CD8 +
T cells, a subset of CD8 + T cells with proposed suppressor func-
tion (Mollet et al., 1998), after myeloablative AHSCT (Muraro
et al., 2005). We have reproduced and extended this observation
in the present study of non-myeloablative AHSCT. CD8 +CD57 +
T cells were significantly and persistently increased throughout the
post-transplantation follow-up. Functional characterization of
CD57 and CD57 + CD8 T cells through co-culture suppression
assays showed that although both populations contained cells with
suppressive activity, the suppressive effect of CD57 +CD8 + cells
was variable and either much greater or equal to their CD57
counterpart. This variability suggested that CD57 may not be
per se a marker defining immunoregulatory CD8 + T cells.
Interestingly, we observed that ILT2, a marker associated with
regulatory function, is expressed by a majority of CD57 + CD8 +
cells and is differentially regulated during the post-AHSCT
follow-up (data not shown). Further work is required to define
the key determinants of regulatory activity of cell populations
within the CD8 +CD57 + subset.
Our detailed characterization of CD8 + T cell reconstitution
included several natural killer markers known to be expressed on
T, natural killer T and natural killer-like T cells (data not shown)
and revealed that a CD161highCD8 + T subset, readily detectable in
all patients before treatment, was radically depleted after AHSCT.
We also demonstrate that 490% of the CD161highCD8 + cell
population in multiple sclerosis patients express TCRV7.2 and
IL-18R, and therefore represent MAITs, a subset recently
described for their antimicrobial activity (Le Bourhis et al., 2010;
Kjer-Nielsen et al., 2012). MAITs have been described as non-
cycling, tissue-targeted cells that secrete IL-17 and express high
AHSCT resets immune balance in MS Brain 2013: 136; 2888–2903 | 2899
levels of the multiple drug transporter protein ABCB1, which con-
fers them resistance to ABCB1-effluxed chemotherapy (Dusseaux
et al., 2011). We confirmed that high expression of CD161 de-
fines a proinflammatory CD8 + memory MAIT population that pro-
duces IFN- and contains the IL-17 producing CD8 + T cells in
patients with multiple sclerosis, in agreement with recent studies
describing CD161high cells as a chemotherapy-resistant and tissue-
homing proinflammatory CD8 + subpopulation (Turtle et al., 2009;
Billerbeck et al., 2010). These MAITs likely possess some plasticity
depending on the inflammatory environment; it was recently
shown that their IL-17 production was enhanced by co-stimulation
with IL-1b, whereas presence of IL-12 induced a Tc1-like function
(Turtle et al., 2011). Our description of a post-treatment depletion
of CD8 + T cells that produce IL-17 (Tc17) is novel and comple-
mentary to recent data from a study of AHSCT employing a high-
intensity immunosuppressive protocol. Darlington et al. (2013)
demonstrate that the capacity to mount Th17 responses is dimin-
ished post-therapy, although the Th1 responses remain unaltered.
Together, their study and ours suggest that alterations of the Th17
and of the Tc17 pathways might be critically involved in the thera-
peutic mechanism of AHSCT in multiple sclerosis.
The demonstration that MAITs are pro-inflammatory contrasts
with the interpretation of Miyazaki et al. (2011) who despite
describing MAITs as a population that secrete high levels of proin-
flammatory cytokines IL-17 and IFN-, interpret them as immu-
noregulatory cells able to suppress Th1 responses in multiple
sclerosis. We believe that without supportive data from intracellu-
lar cytokine staining assays it is difficult to ascertain whether
MAITs truly inhibit IFN- production from T cells. The interpret-
ation of results from their co-culture system is made problematic
by the fact that ‘MAIT-depletion’ in their co-culture assays was
performed by depletion of CD161 expressing cells, and thus would
have depleted not only CD161high MAITs, but also the widely
present CD161dim effector CD4 (IFN- and IL-17 producing
cells, and even some regulatory populations), cytotoxic CD8
T cells including CD57 +CD8 + cells, and natural killer cells. After
the depletion of several functionally important cell subsets, it is
difficult to define the effect of any one specific cell population.
In our study, by intracellular cytokine staining and selective gating
on CD161high, -dim and -negative cells we demonstrate produc-
tion of IL-17, IFN- and TNF- and no production of IL-10 by
CD161high cells, consistent with a pro-inflammatory function
and in agreement with a majority of other studies (Billerbeck
et al., 2010; Annibali et al., 2011; Dusseaux et al., 2011;
Walker et al., 2012).
The involvement of IL-17 producing CD161highCD8 + T cells in
multiple sclerosis pathology is plausible when considering that the
majority (470%) of CD8 T cells in acute and chronic active mul-
tiple sclerosis lesions were reported to express IL-17 (Tzartos et al.,
2008). The potential relevance of CD161highCD8 + cells in multiple
sclerosis was recently underpinned by the study by Annibali et al.
(2011) that showed that the expression of KLRB1, the gene
coding for CD161 and one of the non-major histocompatibility
complex risk alleles with the highest statistical association to mul-
tiple sclerosis (Hafler et al., 2007), was increased in affected
monozygotic twins as compared to their healthy co-twins. In
that study, the frequency of CD161 + cells in the CD8 + T cell
subset was significantly increased in the blood of patients with
multiple sclerosis when compared with healthy controls.
Furthermore, CD161 +CD8 + T cells were detected amongst
tissue-infiltrating cells in post-mortem multiple sclerosis brain
tissue (Annibali et al., 2011).
Here, by examining immune cell infiltrates in post-mortem mul-
tiple sclerosis brain white matter tissue from cases with high levels
of inflammation we confirm that MAITs are present in white
matter lesions, as predicted from their tissue-homing receptor pro-
file. In a separate study extensively characterizing CD161 +
lymphocytes in multiple sclerosis tissue we have quantified the
number of MAITs in the white matter as well as in the meningeal
inflammatory infiltrates, where they represented 17% and 8% of
total CD161 + cells, respectively (Carassiti et al., manuscript sub-
mitted). These data extend the previous demonstration of the
TCRV7.2J33-transcript in white matter lesions (Illes et al.,
2004), and their frequency in highly active cases’ lesions suggest
that MAITs are probably implicated in the development of CNS
immune-mediated injury in multiple sclerosis.
CD161highCD8 + MAITs express CCR6, a receptor that is
involved in transmigration of T cells into the CNS and in the ini-
tiation of experimental autoimmune encephalomyelitis (Reboldi
et al., 2009). CD161 itself also plays a role in trans-endothelial
migration of T cells (Poggi et al., 1997). MAITs produce high
levels of inflammatory cytokines IFN- and TNF-, and are the
highest CD8 + producers of IL-17; IL-17R is expressed on blood–
brain barrier epithelial cells in multiple sclerosis lesions and IL-17
increases the permeability of the barrier (Kebir et al., 2007).
Furthermore, the commensal gut flora has been shown to enhance
the IL-17 response and to be required for the development of
myelin-specific autoimmunity in an experimental model of demye-
lination (Berer et al., 2011), which corroborates the implication of
gut immunity in autoimmune disease. Taken together, these stu-
dies and our own data strongly suggest an important role for
CD161highCD8 + MAITs in multiple sclerosis pathogenesis.
It was, therefore, of great interest to consider to which extent
the two principal components of the immunoablative chemo–
biological therapy conditioning regimen, high-dose cyclophospha-
mide and alemtuzumab contributed to the observed depletion of
MAITs. We hence obtained peripheral blood mononuclear cell
from patients treated in a protocol using high-dose cyclophospha-
mide at Johns Hopkins University, USA; and in a protocol of
alemtuzumab at the University of Cambridge, UK. There was no
post-therapy depletion of MAITs in two of six analysed high-dose
cyclophosphamide treated patients. The frequency of MAITs
peripheral blood mononuclear cells obtained from patients treated
with alemtuzumab was not statistically different from AHSCT trea-
ted patients although the significantly greater variance suggested
that the frequency was higher in some alemtuzumab monother-
apy-treated individual. This variance was independent of the time
since the last treatment infusion. Our data suggest that both high-
dose cyclophosphamide and alemtuzumab alone have the poten-
tial to deplete circulating MAITs but larger numbers of cells may
escape depletion from either treatment alone than from autolo-
gous haematopoietic stem cell transplantation with a conditioning
regimen that includes both cyclophosphamide and alemtuzumab.
Based on our data we speculate that alemtuzumab may account
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for the majority of the MAIT-depleting effect, but that the
combination of alemtuzumab with cyclophosphamide in the trans-
plantation conditioning regime (which was also preceded by a few
weeks by the use of cyclophosphamide for haematopoietic cell
mobilization, which may contribute to the ablative effect) may
have additive or synergistic effects, resulting in a more complete
depletion.
Differentiating responders and non-responders to a given treat-
ment and measuring potentially relevant biological variables might
allow us to gain valuable insight into its mechanism of action.
Dichotomizing clinical responses to therapy, however, is not
always straightforward. Clinical and MRI follow-up of the
AHSCT patients showed complete disease remission post-therapy
in 8 of 12 patients. Four patients had a single relapse during
the first 2 years post-transplantation (versus two relapses each in
the 12 months before transplantation) yet at the end of the
524 month follow-up post-AHSCT the Expanded Disability
Status Scale scores of all relapsing patients were either improved
(n = 3) or unchanged (n = 1) compared to pretreatment baseline,
suggesting that their multiple sclerosis course had been stabilized
or at least attenuated. For the interpretation of our immunological
studies, therefore, we felt more appropriate to regard the clinical
outcomes in these four patients as partial/incomplete responses
rather than treatment failure, and we show here the immunolo-
gical results from all patients conjointly. We applied the same con-
sideration to the other treatments. Indeed, stratification analysis
showed no statistically significant differences between the com-
plete and partial responders groups in any of the immune param-
eters being investigated (data not shown), including recovery of
CD4 + T cell numbers and CD4/8 ratios that were recently
described as surrogate marker of treatment response to alemtuzu-
mab (Cossburn et al., 2013), although we cannot rule out that
some differences might have been detected if larger numbers of
patients had been available.
Based on the pro-inflammatory profile of MAITs, their radical
post-therapy depletion of MAITs observed after AHSCT and the
more variable depletion observed after other treatments we
hypothesized that their frequency might align most closely with
therapeutic efficacy. Our study had not been designed to examine
a correlation of MAIT numbers and clinical or imaging response to
treatment and was statistically underpowered to detect such po-
tential correlations. Only a descriptive analysis of a potential asso-
ciation, therefore, was performed. In the AHSCT cohort, it was of
note that the only two post-therapy samples in which CD8 +
MAITs frequency exceeded 1% (1.1% in both) were from two
time points of two patients who subsequently had a relapse.
Interestingly, we detected enhanced T cell reactivity to myelin
basic protein at one of these time points. In the high-dose cyclo-
phosphamide cohort, one of two patients with high (410%)
CD8 + MAIT frequency post-therapy had an inflammatory flare
with high number of enhancing lesions; the other patient re-
mained stable. In the alemtuzumab cohort, the two patients
with high CD8 + MAIT frequency post-therapy (3.6% and
7.4%) both had relapses post-therapy, although their annualized
relapse rate post-treatment was much lower than in the
12 months preceding treatment with alemtuzumab. Interestingly,
all four patients with high MAIT frequency post-therapy in the
high-dose cyclophosphamide, and in the alemtuzumab cohorts,
had high disability levels pretreatment, although disability im-
proved (even if relapses occurred) in the two patients who
received alemtuzumab, which has been suggested to exert neuro-
protective effects in vivo based on the demonstration of induction
of neurotrophic mediators in vitro (Jones et al., 2010).
Although these observations are intriguing and support the im-
plication that MAITs are active perpetrators of inflammatory dis-
ease activity in multiple sclerosis, it should be noted that in all
three cohorts (AHSCT, high-dose cyclophosphamide and alemtu-
zumab), there were patients with low circulating MAITs who had
relapses or MRI activity post-therapy; and there was one case
(Patient HiCy1) who had high circulating MAIT frequency yet
remained clinically stable. These observations suggest that there
is no exclusive association of low frequency of circulating MAITs
with disease remission; or exclusive association of high frequency
of circulating MAITs with disease relapse. The results, therefore,
should be interpreted with caution. Future studies in larger
numbers of patients, with prospective enumeration of MAITs
and clinical monitoring before and during treatment are warranted
to establish if a correlation of MAIT number and clinical course
exists. These studies could address the hypotheses generated from
the present study that MAITs are implicated as detrimental inflam-
matory mediators of disease and may represent a biomarker of
treatment response in multiple sclerosis.
In conclusion, our data show significant qualitative and func-
tional changes in the reconstituted immune response following
the non-myeloablative AHSCT regimen. Data on differentiation
factors describing a reciprocal relationship between regulatory
T cells and Th17 cells (Bettelli et al., 2007; Mucida et al., 2007)
suggest that the balance between regulatory and pro-inflamma-
tory cells is reset by tightly controlled processes that coordinate
functional differentiation of lymphocytes during immune reconsti-
tution. Indeed, following AHSCT we demonstrate increased num-
bers of circulating cells with regulatory potential as well as the
effective depletion of a pro-inflammatory IL-17, TNF- and IFN-
-producing CD8 + cell subset, which corresponds phenotypically
and functionally to the recently described gut-derived MAIT popu-
lation. We further show that CD8 + MAITs, which express CCR6,
infiltrate multiple sclerosis lesion tissue. Taken together, our results
suggest that CD8 + MAITs might be involved in multiple sclerosis
as inflammatory mediators and could represent a disease and a
treatment biomarker as well as, potentially, a therapeutic target.
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